Bisophosphonates in the treatment of osteoporosis in women with breast cancer

Joanna Wolska


Osteoporosis is the most common skeletal disorder. It is characterized by a decrease in bone density, which results in a greater likelihood of hip, vertebral and long bone fractures. Women who are undergoing hormonal treatment for hormone-related breast cancer are particularly at risk for osteoporosis. Among women diagnosed with premenopausal breast cancer, therapeutic activities may result in secondary loss of ovarian function or include complete hormonal blockade.
Long-term reduction of estrogen concentration adversely affects bone metabolism. It is recommended to assess the risk of bone fractures with densitometry in patients with hormone blockade effects. Calcium and vitamin D supplementation, moderate exercise is recommended. If bone mineral density is reduced, consideration should be given to initiating bisphosphonate therapy.
Bisphosphonates inhibit bone resorption mediated by osteoclasts. The most important is the division into two classes: compounds containing no nitrogen (called simple bisphosphonates) and containing nitrogen. This division carries a significant difference in the strength of bone resorption inhibition and a different mechanism of action.


breast cancer; osteoporosis; bisphosphonates

Full Text:



Watts NB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin N Am. 1998;27(2):419–39

Pieńkowski T. Znaczenie inhibitorów aromatazy w leczeniu chorych na raka piersi. Onco Review. 2012; 2 (3): 173-181

Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc Mayo Clin. 2008;83(9):1032–45

Russell RG, Bisphosphonates: the first 40 years. Bone. 2011;(49): 2-19

Roelofs AJ, Stewart CA, Sun S, Błażewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J. Bone Miner. Res. 2012;(27): 835 - 847 .

Clézardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class . Bone 2011;(48): 71 - 79 .

Widler L, Jahnke W, Green JR. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics Anticancer Agents Med. Chem. 2012; (12): 95- 101.

Watts NB. Diab Long-Term Use of Bisphosphonates in Osteoporosis. The Journal of Clinical Endocrinology and Metabolism. 2010; (95): 1555 – 1565

Mcclung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126 (1):13-20

Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003; (9): 2643 - 2658.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.

Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38(5): 617-27.

Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004 ; 15; 350(16): 1655-64.

Russell R.G., Xia Z., Dunford J.E. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N. Y. Acad. Sci. 2007; 1117: 209–257.

Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 2010; 16: 2950–2960.

Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 2006; 12: 6222 –6230.

Wong MHF, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012; 15;(2)

Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003; 327(7413): 469.

Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016; 27(3): 379–390.



  • There are currently no refbacks.

Copyright (c) 2019 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski